Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck CancerRavindra Uppaluri, Douglas Adkins, Robert I. Haddad et al.|New England Journal of Medicine|2025Cited by 277
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapyDan P. Zandberg, Ricard Mesı́a, Éva Remenár et al.|European Journal of Cancer|2018Cited by 267
Tipifarnib in Head and Neck Squamous Cell Carcinoma With<i>HRAS</i>MutationsAlan L. Ho, Antonio Gualberto, Irene Braña et al.|Journal of Clinical Oncology|2021Cited by 196
KEYNOTE-689: Phase 3 study of adjuvant and neoadjuvant pembrolizumab combined with standard of care (SOC) in patients with resectable, locally advanced head and neck squamous cell carcinoma.Ravindra Uppaluri, Douglas R. Adkins, Nancy Y. Lee et al.|Journal of Clinical Oncology|2019Cited by 51
Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenograftsIrene Braña, Ming‐Sound Tsao|Oncotarget|2017Cited by 39